Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Cash: 2014-2025

Historic Change in Cash for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to -$35.7 million.

  • KalVista Pharmaceuticals' Change in Cash fell 508.44% to -$35.7 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$17.1 million, marking a year-over-year increase of 29.88%. This contributed to the annual value of $100.5 million for FY2025, which is 510.99% up from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Change in Cash of -$35.7 million as of Q2 2025, which was down 466.47% from $9.7 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Change in Cash registered a high of $9.7 million during Q4 2024, and its lowest value of -$35.7 million during Q2 2025.
  • Moreover, its 3-year median value for Change in Cash was $59,000 (2024), whereas its average is -$7.2 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Change in Cash surged by 100.86% in 2024, and later plummeted by 508.44% in 2025.
  • Over the past 3 years, KalVista Pharmaceuticals' Change in Cash (Quarterly) stood at $8.3 million in 2023, then grew by 17.88% to $9.7 million in 2024, then crashed by 508.44% to -$35.7 million in 2025.
  • Its Change in Cash stands at -$35.7 million for Q2 2025, versus $9.7 million for Q4 2024 and $59,000 for Q3 2024.